{
  "id": "5509ec41c2af5d5b70000006",
  "type": "yesno",
  "question": "Is HER2 active only when it dimerizes?",
  "ideal_answer": "Yes, HER2 activation is driven by the formation of various dimer complexes between members of this receptor family.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/21908901",
    "http://www.ncbi.nlm.nih.gov/pubmed/23783223",
    "http://www.ncbi.nlm.nih.gov/pubmed/22983903",
    "http://www.ncbi.nlm.nih.gov/pubmed/21630056",
    "http://www.ncbi.nlm.nih.gov/pubmed/22782294",
    "http://www.ncbi.nlm.nih.gov/pubmed/23990774",
    "http://www.ncbi.nlm.nih.gov/pubmed/23988598",
    "http://www.ncbi.nlm.nih.gov/pubmed/22829865",
    "http://www.ncbi.nlm.nih.gov/pubmed/21538107",
    "http://www.ncbi.nlm.nih.gov/pubmed/21147694",
    "http://www.ncbi.nlm.nih.gov/pubmed/23342251",
    "http://www.ncbi.nlm.nih.gov/pubmed/19934333",
    "http://www.ncbi.nlm.nih.gov/pubmed/23474221"
  ],
  "snippets": [
    {
      "text": "HER activation is driven by the formation of various dimer complexes between members of this receptor family.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23990774",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "rtuzumab is the first humanized monoclonal antibody in a new class of drugs, the HER dimerization inhibitors, approved by the Food and Drug",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23988598",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pertuzumab is a novel anti-HER2 monoclonal antibody, which blocks HER2 dimerization with other ligand-activated HER family members. Here, we explored the complement-mediated anti-tumor effects of trastuzumab and pertuzumab on HER2-positive tumor cells of various histological origins.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23474221",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ays. In this study, we report that an anti-HER2 monoclonal antibody (HER2Mab), which blocks HER2 dimerization with HER3, induces HER3 dimerization with EGFR in both low and high HER2 expressing cancer cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23342251",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recent evidence from both basic and clinical studies suggests that ERBB3 (HER3) serves as a key activator of downstream signaling through dimerization with other ERBB proteins and plays a critical role in the widespread clinical resistance to EGFR and HER2 targeting cancer therapies. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23342251",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "HER3 intracellular domains play a crucial role in HER3/HER2 dimerization and activation of downstream signaling pathways.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22983903",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Dimerization among the EGFR family of tyrosine kinase receptors leads to allosteric activation of the kinase domains of the partners.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22983903",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our results show that quantification of HER dimerization provides information about receptor activation that cannot be obtained by quantification of single receptors. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22829865",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pertuzumab is a novel humanized monoclonal antibody that blocks human epidermal growth factor receptor 2 (HER2) dimerization. It was recently approved by the US FDA for use in combination with trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22782294",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "he HER dimerization status may be more important than HER receptor expression per se in determining sensitivity or resistance to a given therapeutic agen",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21908901",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " and HER2 dimerization inhibitors",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21630056",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "One of the mechanisms by which tumor cell proliferation can be inhibited consists in hampering HER2 dimerization by targeting its extracellular domain with specific antibodies. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21538107",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pertuzumab, a humanized monoclonal antibody, is the first HER2 dimerization inhibitor. It binds to the dimerization site on the HER2 domain and prevents ligand-driven pairing of HER2 with other HER receptors, thus inhibiting tumor cell growth and survival",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21147694",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pertuzumab, another monoclonal antibody, is a HER2 dimerization inhibitor that binds to a different epitope on HER2 than trastuzumab and inhibits HER2 dimer formation with other HER family members such as HER3 and HER1. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19934333",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055503",
    "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0038134",
    "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0038135",
    "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0042803",
    "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0038133",
    "http://www.disease-ontology.org/api/metadata/DOID:0060079",
    "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018719",
    "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019281",
    "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0046983",
    "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018734",
    "http://www.disease-ontology.org/api/metadata/DOID:0060080"
  ],
  "exact_answer": "Yes"
}